Am J Perinatol 2025; 42(06): 699-707
DOI: 10.1055/a-2405-1381
Review Article

Daily versus Alternate-Day Iron Supplementation for Pregnant Women with Iron Deficiency Anemia: A Randomized Controlled Trial

Authors

  • Melissa Chu Lam

    1   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Northshore University Hospital, Manhasset, New York
  • Binny Khandakar

    2   Department of Pathology, Mount Sinai West, New York, New York
  • Isaak Heon

    2   Department of Pathology, Mount Sinai West, New York, New York
  • Farrah Hussain

    3   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Mount Sinai West Hospital, New York, New York
  • Kristina Feldman

    3   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Mount Sinai West Hospital, New York, New York
  • Elianna Kaplowitz

    3   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Mount Sinai West Hospital, New York, New York
  • Jessica R. Overbey

    4   Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York
  • Lois Brustman

    3   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Mount Sinai West Hospital, New York, New York
  • Barak Rosenn

    5   Division of Maternal Fetal Medicine, Jersey City Medical Center, Jersey City, New Jersey

Funding None.
Preview

Abstract

This study aimed to evaluate the most effective regimen to raise hemoglobin (Hb) by comparing alternate-day dosing of iron to daily dosing in pregnant women with iron deficiency anemia. Women with Hb < 11.0 g/dL and ferritin ≤ 25 µg/L between 120/7 and 340/7 weeks' gestation were recruited. A total of 88 patients were randomized using block randomization with 1:1 allocation to receive either 1 tablet of 325 mg ferrous sulfate on consecutive days or 2 tablets every other day. The primary outcome, the change in Hb after 6 weeks of treatment was assessed using an analysis of covariance to adjust for baseline level. Secondary outcomes included change in ferritin, hepcidin, side effects, and compliance. Patients completed a questionnaire to assess for adverse symptoms and adherence was monitored by installing a pill reminder app on smartphones of patients. A total of 88 patients were consented. The daily iron group had a greater proportion of nulliparous women (40 vs. 7%). Most patients (98%) had mild anemia (Hb: 9–10.9 g/dL) at recruitment, with a median gestational age of 28.1 weeks (interquartile range [IQR]: 25.6, 30.9) and median duration of treatment of 42 days (IQR: 35, 45). At 6 weeks, the daily iron group had a mean increase in Hb of 0.8 ± 0.9 g/dL, whereas the alternate-day iron group had a mean increase of 0.5 ± 1.0 g/dL (baseline adjusted difference of means: −0.3 [95% confidence interval: −0.7, 0.1], p = 0.15). Frequency of adverse effects attributable to iron were similar between groups. Patient self-reported compliance to treatment was also similar between groups. Among those that used the app, compliance was higher among the daily group compared with the alternate daily group (median: 95.5% [IQR: 75, 100] vs. 85% [IQR: 40, 92]), although this difference was not statistically significant (p = 0.07). This trial suggests that there are no significant differences between alternate-day iron supplementation and daily iron supplementation for treating iron deficiency anemia.

Key Points

  • Intermittent iron provides no additional benefit compared to daily iron in the treatment of anemia.

  • Patient compliance to treatment was similar between the groups.

  • The frequency of side effects was not significantly different between the groups.

Supplementary Material



Publication History

Received: 09 January 2024

Accepted: 25 August 2024

Accepted Manuscript online:
29 August 2024

Article published online:
23 September 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA